ALX ONCOLOGY HOLDINGS INC Q1 FY2026 earnings call

Key highlights include data from ESMO Breast 2026 showing CD47 expression as a key predictive biomarker for EVO in HER2-positive patients; Dr. Sarah Hurwitz presenting ESMO breast data and views on avorbicept's potential; CMO Barb Quincy recapping EVO findings in two trials; update on phase 1 trial of EGFR-targeted ADC AOX 2004; continued progress of both EVO and AOX 2004 programs; completion of key hires and strong financing in Q1; Evorpercept phase two breast trial progressing well; AOX 2004 on track for initial safety readout in second half of 2026; goal to have both programs ready for registrational studies by end of next year.

No specific financial performance data for product segments; focus is on progress of EVO and AOX 2004 programs. EVO showed positive data in HER2-positive cancers with CD47 as a predictive biomarker, and AOX 2004 is progressing in dose escalation for EGFR-expressing cancers.

Both EVO and AOX 2004 programs remain on track, with expected significant data readouts from these programs in the coming 12 to 18 months; Evorpercept phase two breast trial expected to read out 80 patients mid-next year; AOX 2004 on track for initial safety readout in second half of 2026; goal to have both programs ready for registrational studies by end of next year.

No detailed discussion of specific risks and operational failures in the provided transcript

Q: For upcoming interim data readout in mid-2027 from Aspen breast study, what's compelling results in terms of ORR and DOR, and plan to put out NPFS data.

A: Expecting response rate assessment, duration of response may be preliminary, PFS possibly too immature; Q: How to use drug in clinical setting if approved and role of CD47 testing.

A: Aspen 09 study to validate data, potential companion diagnostic development with Ventana, cut point to be set; Q: Population in Aspen 09 and comparison to update today, cutoff for CD47, further development of ZANI combo.

A: Population similar, cutoff being optimized, targeted phase three study; Q: Companion diagnostic development and statistical powering.

A: Working on companion diagnostic, targeted approach allows tighter registrational study; Q: Consistency of CD47 high observation in Aspen 09, tissue adequacy and turnaround time.

A: Monitoring closely, no urgency for current study as it's single-arm; Q: Nuances of CD47 high cutoffs used.

A: Cutoffs may change, optimized with Aspen 09 data, cumulative total calculation in IHC